AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mlrb2113 who wrote (311)	11/1/2007 1:29:45 AM
From: Clarksterh	Read Replies (2) of 332

ml - Rob Scott said the indications of liver toxicity were no worse than in statins. We've discussed this before, but I'll repeat. I'll give him the benefit of the doubt and assume he is talking about elevated ALT. By this metric 1067 is perhaps in approximately the same ballpark as statins. But that isn't the problem with 1067 - it is the elevated bilirubin. And statin trials have NOT induced that (caveat: it is possible that there is a bilirubin issue in the high dose trials but we don't know because the drug companies have never submitted this data to the FDA for label expansion). As I have said before, Rob Scott was good because he was open. But he was not remotely a trustworthy data analysis type of person. Talk to you in another 4 months when you forget this again -g-.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next